FDA Collaborates With AbbVie to Track Down Counterfeit Botox Injections

On Tuesday, April 16, the FDA alerted consumers and health care professionals alike to widely distributed counterfeit versions of Botox that were administered to consumers across Colorado, Nebraska, Illinois, Florida, Kentucky, New York, Washington, and Tennessee. According to a recent Reuters article, individuals who received these injections are experiencing adverse reactions to the counterfeit drug.

Nineteen individuals from the mentioned states experienced adverse effects following the administration of counterfeit injections, all administered by unlicensed or inadequately trained personnel.

The FDA is collaborating with AbbVie, the manufacturer of Botox, in an ongoing investigation to locate counterfeit injections.

AbbVie is a biopharmaceutical company dedicated to the research, development, manufacturing, commercialization, and sale of various medications and therapies, including numerous anesthetics products and fillers.

References

US FDA warns of harmful reactions to fake Botox injections. Reuters. Published April 16, 2024. Accessed April 16, 2024. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-warns-harmful-reactions-fake-botox-injections-2024-04-16/

AbbVie Inc. Reuters. Updated April 16, 2024. Accessed April 16, 2024. https://www.reuters.com/markets/companies/ABBV.N